TrialThe oncologist2021

A Randomized Phase II Study of AGS-16C3F Versus Axitinib in Previously Treated Patients with Metastatic Renal Cell Carcinoma.

Christian Kollmannsberger et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.